Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2003 3
2004 5
2005 8
2006 5
2007 2
2008 6
2009 4
2010 13
2011 13
2012 13
2013 21
2014 12
2015 22
2016 14
2017 17
2018 33
2019 21
2020 30
2021 22
2022 50
2023 40
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

333 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for xiang yan yan
Search for Xiangyan Yan instead (3 results)
Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial.
Yan X, Li X, Liu B, Huang J, Xiang Y, Hu Y, Tang X, Zhang Z, Huang G, Xie Z, Zhou H, Liu Z, Wang X, Leslie RD, Zhou Z. Yan X, et al. Signal Transduct Target Ther. 2023 Apr 20;8(1):158. doi: 10.1038/s41392-023-01369-9. Signal Transduct Target Ther. 2023. PMID: 37076476 Free PMC article. Clinical Trial.
Carbon Dots in Biomedicine: A Review.
Zhu P, Wang S, Zhang Y, Li Y, Liu Y, Li W, Wang Y, Yan X, Luo D. Zhu P, et al. Among authors: yan x. ACS Appl Bio Mater. 2022 May 16;5(5):2031-2045. doi: 10.1021/acsabm.1c01215. Epub 2022 Apr 20. ACS Appl Bio Mater. 2022. PMID: 35442016 Review.
Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.
Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H. Weng J, et al. Among authors: yan x. Lancet. 2008 May 24;371(9626):1753-60. doi: 10.1016/S0140-6736(08)60762-X. Lancet. 2008. PMID: 18502299 Clinical Trial.
[Complement in atherogenesis].
Liu YM, Yan X, Liu YY. Liu YM, et al. Among authors: yan x. Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Sep;33(9):866-9. Zhonghua Xin Xue Guan Bing Za Zhi. 2005. PMID: 16266467 Review. Chinese. No abstract available.
Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial.
Dai Z, Zhu R, Sheng Z, Qin G, Luo X, Qin Q, Song C, Li L, Jin P, Yang G, Cheng Y, Peng D, Zou C, Wang L, Shentu J, Zhang Q, Zhang Z, Yan X, Fang P, Yan Q, Yang L, Fan X, Liu W, Wu B, Cui R, Wu X, Xie Y, Shu C, Shen K, Wei W, Lu W, Chen H, Zhou Z. Dai Z, et al. Among authors: yan x. Front Endocrinol (Lausanne). 2023 Apr 5;14:1168757. doi: 10.3389/fendo.2023.1168757. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37091850 Free PMC article. Clinical Trial.
Current understanding on the role of CCT3 in cancer research.
Liu W, Lu Y, Yan X, Lu Q, Sun Y, Wan X, Li Y, Zhao J, Li Y, Jiang G. Liu W, et al. Among authors: yan x. Front Oncol. 2022 Sep 15;12:961733. doi: 10.3389/fonc.2022.961733. eCollection 2022. Front Oncol. 2022. PMID: 36185198 Free PMC article. Review.
333 results